行情

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

实时行情|Nasdaq Last Sale

7.99
-0.01
-0.13%
盘后: 7.99 0 0.00% 16:00 06/16 EDT
开盘
7.95
昨收
8.00
最高
8.15
最低
7.88
成交量
27.25万
成交额
--
52周最高
25.50
52周最低
2.410
市值
3.00亿
市盈率(TTM)
-7.7731
分时
5日
1月
3月
1年
5年
简报-Cardiff Oncology 宣布在 Onvansertib 联合伊立替康和 5-Fu 治疗胰腺癌的第 2 期试验中对首例患者给药
reuters.com · 06/08 13:25
Cardiff Oncology 在 Onvansertib 联合疗法治疗胰腺癌的中期研究中为首位患者给药
MT Newswires · 06/08 11:30
周五盘中交易中的12种保健股
 
Benzinga · 05/21 16:37
卡迪夫肿瘤学(CRDF)获得HC Wainwright的买入评级
SmarterAnalyst · 05/10 12:27
HC Wainwright&Co.维持对Cardiff Oncology的买入评级,将目标价格下调至25美元
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $27 to $25.
Benzinga · 05/10 11:13
--HC Wainwright将卡迪夫肿瘤学(Cardiff Oncology)PT从27美元上调至25美元,维持买入评级
MT Newswires · 05/10 09:28
卡迪夫肿瘤学(CRDF)报告第一季度亏损,未达到收入估算
Zacks.com · 05/06 23:05
卡迪夫肿瘤学第一季度每股收益从去年的(0.41)美元升至(0.14)美元
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share. This is a 65.85 percent increase over losses of $(0.41) per share from the same period last year.
Benzinga · 05/06 21:24
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CRDF最新的财务预测,通过CRDF每股收益,每股净资产,每股现金流等数据分析Cardiff Oncology Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CRDF价格均价为26.67,最高价位30.00,最低价为25.00。
EPS
机构持股
总机构数: 88
机构持股: 2,458.82万
持股比例: 65.48%
总股本: 3,755.21万
类型机构数股数
增持
32
535.09万
建仓
18
232.55万
减持
13
493.10万
平仓
28
530.27万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.64%
制药与医学研究
-0.46%
高管信息
Chairman/Director
Rodney Markin
Chief Executive Officer/Director
Mark Erlander
Director
Thomas Adams
Independent Director
James Armitage
Independent Director
Paul Billings
Independent Director
John Brancaccio
Independent Director
Gary Jacob
Independent Director
Mani Mohindru
Independent Director
Gary Pace
Independent Director
Renee Tannenbaum
Independent Director
Lale White
暂无数据
CRDF 简况
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.

微牛提供Cardiff Oncology Inc(NASDAQ-CRDF)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRDF股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRDF股票基本功能。